| Induction of phase 3 of the migrating motor complex in human small intestine by trimebutine. | |
| | |
MedLine Citation:
|
PMID: 2820749 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The effects of trimebutine, a drug used in the treatment of various gastrointestinal motility disorders, have been investigated fed and fasted healthy subjects. Duodenojejunal motility was recorded manometrically with a 4-lumen probe. Trimebutine 50 or 100 mg was injected i.v. 3 or 25 min after observing a spontaneous Phase 3 complex in the fasted state. Other experiments were done in the postprandial state and after intravenous naloxone 0.8 mg. In the fasted state, trimebutine 100 mg, injected 25 min after a spontaneous Phase 3 complex consistently induced a premature Phase 3 complex. The mean duration of the migrating motor complex cycle decreased from 86.4 +/- 10.8 min to 32.5 +/- 1.0 min. Trimebutine 50 mg injected 3 and 25 min after a spontaneous Phase 3 complex did not significantly modify the periodicity of the migrating motor complex. Trimebutine 100 mg initiated Phase 3-like activity in the post-prandial state. Previous intravenous administration of naloxone 0.8 mg (Narcan) suppressed the stimulatory action of TMB. Thus, trimebutine is able to modify the motility pattern in the small intestine of man, possibly by acting at opioid receptors. |
| | |
Authors:
|
S Chaussade; S Grandjouan; D Couturier; D Thierman-Duffaud; J F Henry |
Related Documents
:
|
9048269 - Safety and tolerance of methylnaltrexone in healthy humans: a randomized, placebo-contr... 2452249 - Irreversible opiate agonists and antagonists. iv. analgesic actions of 14-hydroxydihydr... 2137549 - Partial reversal of behavioral action of the agonist d-trp-6-lh-rh by naloxone in mice. 10913589 - Antinociceptive effects of nigella sativa oil and its major component, thymoquinone, in... 10340299 - Selective nmda nr2b antagonists induce antinociception without motor dysfunction: corre... 7855219 - Effects of naloxone on diurnal rhythms in mood and endocrine function: a dose-response ... 8336309 - Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (s... 7487999 - N-acetylcysteine diminishes injury induced by balloon angioplasty of the carotid artery... 19071129 - Systemic administration of diarylpropionitrile (dpn) or phytoestrogens does not affect ... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: European journal of clinical pharmacology Volume: 32 ISSN: 0031-6970 ISO Abbreviation: Eur. J. Clin. Pharmacol. Publication Date: 1987 |
Date Detail:
|
Created Date: 1987-11-17 Completed Date: 1987-11-17 Revised Date: 2004-11-17 |
Medline Journal Info:
|
Nlm Unique ID: 1256165 Medline TA: Eur J Clin Pharmacol Country: GERMANY, WEST |
Other Details:
|
Languages: eng Pagination: 615-8 Citation Subset: IM |
Affiliation:
|
Service d'Hépatogastroentérologie, Hôpital Cochin, Paris, France. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Benzoates / pharmacology* Female Gastrointestinal Motility / drug effects* Humans Male Naloxone / pharmacology Receptors, Opioid / drug effects Trimebutine / pharmacology* |
| Chemical | |
Reg. No./Substance:
|
0/Benzoates; 0/Receptors, Opioid; 39133-31-8/Trimebutine; 465-65-6/Naloxone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Phase II evaluation of trans-N3P3Az2(NHMe)4 (AZP) in non-small cell lung cancer.
Next Document: The cytosolic free calcium in anti-mu-stimulated human B cells is derived partly from extracellular ...